![Aldevron logo image](https://www.ta.com/system/uploads/fae/image/asset/3073/xs_Aldevron_DETAIL.jpg 320w,https://www.ta.com/system/uploads/fae/image/asset/3073/sm_Aldevron_DETAIL.jpg 640w,https://www.ta.com/system/uploads/fae/image/asset/3073/md_Aldevron_DETAIL.jpg 1024w,https://www.ta.com/system/uploads/fae/image/asset/3073/lg_Aldevron_DETAIL.jpg 1400w,https://www.ta.com/system/uploads/fae/image/asset/3073/xl_Aldevron_DETAIL.jpg 1800w,https://www.ta.com/system/uploads/fae/image/asset/3073/xxl_Aldevron_DETAIL.jpg 2400w)
Date July 31, 2019
EQT to acquire majority interest in Aldevron, the leading global supplier of plasmid DNA used in cell and gene therapies
EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey